Birch Hill Investment Advisors LLC Has $1.01 Million Stake in Kenvue Inc. $KVUE

Birch Hill Investment Advisors LLC decreased its position in Kenvue Inc. (NYSE:KVUE) by 57.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 62,488 shares of the company’s stock after selling 83,483 shares during the quarter. Birch Hill Investment Advisors LLC’s holdings in Kenvue were worth $1,014,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Kenvue by 1.8% in the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after acquiring an additional 4,101,880 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Kenvue by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock valued at $1,021,267,000 after purchasing an additional 604,953 shares during the last quarter. Independent Franchise Partners LLP boosted its holdings in Kenvue by 233.4% in the second quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after purchasing an additional 21,886,537 shares in the last quarter. American Century Companies Inc. increased its position in Kenvue by 38.6% during the second quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock worth $633,447,000 after buying an additional 8,436,166 shares during the last quarter. Finally, Norges Bank bought a new position in Kenvue during the second quarter valued at about $537,418,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.2%

Shares of KVUE opened at $16.72 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The company has a 50-day simple moving average of $16.79 and a 200-day simple moving average of $18.46. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The firm has a market capitalization of $32.03 billion, a P/E ratio of 22.29 and a beta of 0.60.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. During the same period in the previous year, the company posted $0.28 earnings per share. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were paid a dividend of $0.2075 per share. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a yield of 5.0%. Kenvue’s payout ratio is currently 110.67%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Tuesday, October 14th. Bank of America decreased their target price on Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, October 8th. Barclays lifted their price target on shares of Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $22.50 to $22.00 in a report on Friday, September 26th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $20.23.

Insider Transactions at Kenvue

In other Kenvue news, Director Jeffrey C. Smith acquired 3,200,000 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was bought at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the purchase, the director owned 27,307,632 shares in the company, valued at $474,333,567.84. This represents a 13.27% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.68% of the stock is owned by company insiders.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.